PubMed Health⌕ Search

PubMed · 9915119

AChemS: the beginning. Association for Chemoreception Sciences.

Abstract

This paper unfolds the events, the people and the times that led up to the founding of AChemS and fashioned its character during its early formative years. It describes the path over which AChemS came, going from the original assertions and denials for the need of such an organization to its later inception and nascent development. This narration highlights such topics as the debate over the need for AChemS, the role of National Science Foundation in the founding of AChemS, the derivation of the Association's name, the choice of Sarasota and the Hyatt House as the meeting site, the generation of the programs for the early annual meetings, the adoption of the bylaws, the process of incorporation and tax deferment, and the birth of the Givaudan Lectureship. Most emphatically highlighted, however, is the enthusiasm, commitment and hard work that the members of the chemosensory research community displayed in bringing AChemS to fruition.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M M Mozell. 1998. AChemS: the beginning. Association for Chemoreception Sciences.. https://doi.org/10.1093/chemse%2F23.6.721. https://pubmed.health/record/pubmed%3A9915119/achems-the-beginning-association-for-chemoreception-sciences

Citations retain the original authors and DOI and include this site’s record URL. If this discovery service contributed to your research, you can also cite PubMed Health by Indiciae: BibTeX · RIS.

KEEP EXPLORING

Related citations

On-demand therapy for gastroesophageal reflux disease.

The following pages summarize the proceedings of a symposium held in May 2006 on the emerging role of on-demand therapy for gastroesophageal reflux disease (GERD). Medical therapy for GERD has undergone significant change in recent years with the advent of effective, but expensive, antisecretory agents. On-demand (patient-driven) therapy is attractive to payers and patients, because it appears to be both cost-effective and convenient. Many individuals appear to accept occasional symptomatic breakthrough in exchange for personal control of their disease. On-demand therapy should be distinguished from intermittent therapy, which is either patient- or physician-driven, but which requires intermittent episodes of continuous therapy followed by discontinuation until symptoms recur. Proton pump inhibitors appear to be effective on-demand agents despite theoretical pharmacodynamic limitations for this class of drug. The available data support the use of on-demand therapy for GERD in uninvestigated reflux disease, nonerosive reflux disease, and possibly mild esophagitis as well. On-demand therapy should not be considered for patients with severe esophagitis.

Congresses as Topic↗